Where Do Stem Cells Come From? A Beginner's Guide to Sources and Ethics

What This Article Covers

Every stem cell therapy you've heard about — real or exaggerated — starts with a source: a place in the body, or a laboratory dish, where the cells actually come from. That source shapes everything downstream, including what the cells are legally and ethically allowed to be used for, how flexible they are, and how close (or far) they are from an approved treatment. This guide walks through the three main sources of stem cells used in research and medicine today — embryonic, adult (somatic), and induced pluripotent — and the decades-long ethical and political debate that shaped how each one is studied in the United States.

A Quick Note on What Makes a Cell a “Stem Cell”

We cover the biology of stem cells themselves elsewhere on this site. For this piece, the short version is enough: a stem cell is an unspecialized cell that can both copy itself and turn into more specialized cell types. What differs enormously between stem cells is where they're harvested from and, as a result, how many different cell types they're capable of becoming — a range set almost entirely by source, which is why “where do stem cells come from” is really the first question in the field.

Embryonic Stem Cells and the Ethics Debate

Embryonic stem cells (ESCs) come from the inner cell mass of a very early-stage embryo called a blastocyst, typically one left over from in vitro fertilization (IVF) and donated for research with consent, rather than an embryo created for research purposes. Scientists first developed methods to isolate and grow human ESCs in the lab in 1998, and because these cells are pluripotent — able to become virtually any cell type in the body — they were, and remain, scientifically prized. But deriving them destroys the blastocyst, which is precisely why they became one of the most contested topics in American science policy.

The legal fight starts with the Dickey-Wicker Amendment, a budget rider first enacted in 1996 that bars federal funds from being used to create or destroy human embryos for research. It has been re-attached to federal spending bills every year since and remains in force today. In August 2001, President George W. Bush drew a line consistent with that amendment: federal funding could support research only on roughly 60 ESC lines that already existed as of his announcement, plus $250 million toward non-embryonic sources like umbilical cord, placental, and adult stem cells — but not on new lines derived afterward. President Obama reversed that limit with Executive Order 13505 in March 2009, allowing federal funding for research on newly created lines too, provided they came from embryos donated by IVF patients slated for disposal. Dickey-Wicker itself never went away, though — it still bars federal money from paying to derive new embryonic stem cell lines in the first place, so that specific step has generally relied on private or state funding even now.

Adult (Somatic) Stem Cells: Bone Marrow, Fat, and Cord Blood

Adult stem cells — also called somatic stem cells — are found throughout the body in specific tissues, where they act as a built-in repair crew for that tissue. Unlike embryonic stem cells, they don't require destroying an embryo, which has made them far less ethically contentious. The trade-off is versatility: most adult stem cells are multipotent rather than pluripotent, meaning they can typically only become the family of cell types found in the tissue they came from, not any cell type in the body.

The best-known source is bone marrow, home to hematopoietic stem cells (which give rise to blood and immune cells) and mesenchymal stem cells (which can form bone, cartilage, and related tissue). Adipose (fat) tissue is another major source of mesenchymal stem cells, often obtained through routine liposuction, making it popular in both research and the (frequently unproven, direct-to-consumer) clinic setting. A third major source is umbilical cord blood, collected from the placenta and cord after a baby is born; it's rich in hematopoietic stem cells and is the source behind the small handful of treatments that are actually FDA-approved in the U.S. today.

Induced Pluripotent Stem Cells: Yamanaka's Reprogramming Breakthrough

For decades, scientists believed cell specialization was a one-way street — once a skin cell was a skin cell, it stayed that way. Japanese researcher Shinya Yamanaka overturned that assumption. In 2006, his lab showed that inserting just four specific genes (Oct4, Sox2, Klf4, and c-Myc, now often called the “Yamanaka factors”) into ordinary mouse skin cells could reprogram them backward into an embryonic-stem-cell-like pluripotent state. In 2007, his team repeated the feat with human skin cells, showing the technique wasn't a mouse-biology quirk.

The implications were enormous: researchers could now generate pluripotent stem cells capable of becoming nearly any tissue type from a patient's own ordinary adult cells, without touching an embryo. In 2012, Yamanaka shared the Nobel Prize in Physiology or Medicine with British developmental biologist John Gurdon, whose 1962 nuclear-transfer experiments in frogs had first hinted that mature cells could be reprogrammed; the Nobel committee credited the pair with overturning the dogma that cellular development only runs in one direction. iPSCs didn't make embryonic stem cells scientifically obsolete — researchers still use ESCs as a reference standard — but they gave the field a way to study pluripotent cells and model disease largely free of the constraints that had shaped embryonic research for over a decade.

How Source Shapes What's Actually Used in Clinics Today

It's worth being direct about where things stand: as of today, the only stem cell-based treatments with routine FDA approval in the United States are hematopoietic stem cell transplants, primarily using bone marrow or umbilical cord blood, for blood cancers and certain blood and immune disorders. Embryonic stem cells and iPSCs remain overwhelmingly research and clinical-trial tools rather than approved therapies — invaluable for studying disease and testing potential treatments, but not something a patient can currently receive as standard care outside of a trial. Adipose-derived and other mesenchymal stem cell treatments are widely marketed by clinics, but most are not FDA-approved and lack the trial evidence approval requires. Understanding a therapy's source is often the fastest way to tell what stage of development it's actually at.

Bottom Line

Where a stem cell comes from — an early embryo, a patient's own bone marrow or fat tissue, umbilical cord blood, or a reprogrammed skin cell — determines both its scientific potential and the ethical and legal path it has to travel before reaching patients. Embryonic stem cells sparked a genuine, decades-long policy debate in the U.S. that is still shaped by a 1996 budget rider; adult stem cells sidestepped much of that debate but come with real biological limits; and Yamanaka's iPSC breakthrough offered a third path that combines much of the embryonic cells' versatility with far fewer of the ethical objections. None of this makes any single source a shortcut to a cure — as of today, only a narrow set of blood-related treatments have cleared the FDA's bar — but it does make “where did this come from?” one of the most useful questions a newcomer can ask about any stem cell claim.